Geovax Labs Stock Today
| GOVXW Stock | USD 0.1 0.00 0.000001% |
PerformanceInsignificant
| Odds Of DistressVery High
|
GeoVax Labs is selling for under 0.098999999 as of the 17th of February 2025; that is 0 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.099. GeoVax Labs has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 18th of January 2025 and ending today, the 17th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of September 2020 | Category Healthcare | Classification Health Care |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. More on GeoVax Labs
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
GeoVax Stock Highlights
| President Chairman | David Dodd | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
GeoVax Labs can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GeoVax Labs' financial leverage. It provides some insight into what part of GeoVax Labs' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
GeoVax Labs (GOVXW) is traded on NASDAQ Exchange in USA. It is located in 1900 Lake Park Drive, Smyrna, GA, United States, 30080 and employs 17 people. GeoVax Labs is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
GeoVax Labs has accumulated about 710.68 K in cash with (25.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check GeoVax Labs Probability Of Bankruptcy
GeoVax Labs Historical Income Statement
GeoVax Stock Against Markets
GeoVax Labs Corporate Management
| CPA CPA | CFO Sec | Profile | |
| Mark Newman | Chief Officer | Profile | |
| Jeffrey Welch | Head Operations | Profile | |
| Harriet Robinson | Chief Founder | Profile | |
| John Sharkey | Vice Development | Profile |
Additional Tools for GeoVax Stock Analysis
When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.